Investor
Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 431 (CSE: $DOSE.C)
(OTCQB: $ALID) (CSE: $LHS.C) (CSE: $THC.C)
Delta, Kelowna, BC, June 19, 2020 (Investorideas.com Newswire)
www.Investorideas.com, a global news source covering leading sectors including
marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight
from thought leaders and experts.
Listen to the podcast:
Read this in full
at https://www.investorideas.com/news/2020/cannabis-potcasts/06191DOSE-ALID-LHS-THC.asp
Today’s podcast overview/transcript:
Good
afternoon and welcome to another episode of Investorideas.com
"Potcast" featuring cannabis news, stocks to watch as well as
insights from thought leaders and experts.
In
today’s podcast we look at a few public and private company announcements.
Rapid
Dose Therapeutics Corp. (CSE:
DOSE), a Canadian Life Sciences company focused on innovative
drug and active ingredient delivery solutions, announced that it
has filed a non-provisional patent with the USPTO for an “Apparatus for and method of converting cbd and/or cbd derivatives to at
least one other type of cannabinoid and/or cannabinoid derivative such as THC”.
In conjunction with McMaster University and the team lead by Dr. James McNulty,
RDT has discovered a new and efficient way to create THC from CBD. This
selective method can generate delta 8 or
delta 9 THC.
Jason Lewis, RDT SVP and co-inventor
said, “This is an incredible breakthrough for RDT and the industry as a whole.
Our technology could revolutionize the way synthetic THC is created so patients
around the world can have access to a consistent quality of delta 8 or delta 9.
Instead of the industry being dependent on the many complicated variables
associated with growing cannabis and the expense of cultivating indoors, we
created a method to convert hemp-derived CBD to THC. This is the innovation
required to allow pharmaceutical companies to embrace cannabinoid treatments.”
“This process is novel and highly
efficient at selectively converting CBD isolate or distillate into synthetic
THC,” said Dr. McNulty. “Our
collaboration with RDT has resulted in a transformative outcome that we are
proud to be involved with. There are numerous
high yield derivatives we can control for using naturally derived CBD through
the innovative conversion. My team is excited about the possibilities to
provide pure cannabinoids for life science companies.”
The PCT application is a follow up
to the RDT provisional patent filed on April 5, 2019. Mark Upsdell, RDT CEO, said: “Despite the
current COVID situation creating delays around the globe, RDT remains committed
to research and innovation. Our filing
of this patent is an indication that our continued work with McMaster is
aligned with our overall strategy to create unique products aimed at improving
patient outcomes. The ability to combine
this innovation with our unique QuickStrip™ delivery system will create new
opportunities for RDT.”
Allied
Corp.
(OTCQB:
ALID), an international medical cannabis company focused on
creating and providing targeted cannabinoid health solutions to address today’s
medical issues is pleased to announce the initiation of a pharmaceutical human
clinical PHASE I research trial with MGC
Pharmaceuticals.
Under the terms of this agreement,
MGC Pharma will provide a comprehensive suite of pharmaceutical services to
advance Allied’s pharmaceutical products into human clinical PHASE 1. This
trial will test the efficacy and pharmacodynamics of Allied’s pipeline of
proprietary cannabis derived drug candidates targeting Post Traumatic Stress
Disorder (PTSD). The scope of MGC
Pharma’s services will cover clinical research, IMP registration, manufacturing
of lab volumes for the research project, drug stability testing, GMP
manufacturing and regulatory assistance for obtaining an Investigational
Medicinal Product (IMP) number that is needed in order to sell the
pharmaceutical product.
Allied has also conducted an
extensive prior art review on its previously submitted provisional patents for
products AC001 and AC002 and has decided to abandon these. Along with creation
of new formulations, representing the conception of new inventions, and its
prior art review, Allied will submit patent submissions for products ALID-10
and ALID-11. ALID-10 and ALID-11 will be the products entering into the human
clinical trials.
“This agreement with MGC Pharma is a
significant milestone for Allied as we continue to make progress towards
advancing our first cannabis derived pharmaceutical product into clinical
trials for PTSD”, said Calum Hughes, CEO of Allied. “The drug candidates to be developed in our
collaboration with MGC Pharma have been validated by Allied’s research through
preliminary case study evidence conducted by our corporate physician and the
Allied team. We are excited to be working with MGC Pharma, a company with a
proven track record in developing cannabis-based drugs and bringing them to
market. We look forward to leveraging
their technical capabilities to accelerate the development, manufacturing and
sales of our first pharmaceutical product for PTSD”.
Liberty
Health Sciences Inc. (CSE:
LHS)
(OTCQX:
LHSIF), a provider of high quality cannabis, announced
today that it has entered into a licensing agreement with
licensed California adult use and medicinal cannabis company HONEY®, one of
California's largest full service companies, to supply all of Liberty's
dispensaries with the company's full assortment of branded products.
In 2012 HONEY® revolutionized the
cannabis industry by becoming the first producer in the world to market
distilled cannabis oil in vape cartridges. Today, they provide authentic, full
spectrum oil in vape cartridges, applicators, and caps to legal dispensaries
and delivery services.
"We are excited to partner with
HONEY®, a longstanding pioneer and premium brand in the cannabis space,"
said Victor Mancebo, Chief Executive Officer of Liberty. "Adding HONEY® to
our portfolio of brands creates an immediate distinction between other
competitors in the space and reinforces our product offering strategy to provide
variety, quality, and price versatility in all of the products we market."
All THC and CBD oil in HONEY
cartridges are free of fillers and are lab tested to be 75% +/- cannabinoids.
The devices provide the full range of benefits and deliver the precise dosage
of cannabinoids with every use.
"We are
very excited to be partnering with Liberty to introduce our HONEY® products to
the Florida medicinal cannabis market as we started in the California medical
market nearly a decade ago," said Peter Tejera, Chief Executive Officer of
HONEY®. "We look forward to growing
our in-dispensary presence in Florida and this partnership will provide
Floridian consumers with a superior choice of high quality, predictable, and consistent
product experience second to none."
THC
BioMed Intl Ltd. (CSE:
THC)
announced that
its ready-to-drink cannabis beverage shot, THC Kiss, was launched last week on
the bccannabis store website and sold out within hours. THC's fulfillment
department is now preparing its second order to B.C.
"We are very happy with the launch
of THC Kiss so far and excited to offer Canadians a true alternative to smoking
cannabis," commented John Miller, President and CEO of THC BioMed.
Each 30ml bottle of THC Kiss
contains 10 mg of THC.
The Company also announced that it
has entered into a reseller agreement whereby National Cannabis Distribution
will buy and resell cannabis products from the Company as one of two exclusive
resellers of the Company's products in Saskatchewan.
The term of the Agreement is one
year and will automatically renew unless terminated in accordance with the
Agreement.
"National Cannabis Distribution
has impressed us with its distribution network and business methods. We
appreciate that it recognizes the quality and uniqueness of our products and
has selected us as a supplier," said Mr. Miller.
Investor ideas reminds all
listeners to read our disclaimers and disclosures on the Investorideas.com
website and that this podcast is not an endorsement to buy products or services
or securities. Investors are reminded all investment involves risk and possible
loss of investment.
Learn more about
our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
Investorideas.com
podcasts are also available on iTunes,
Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified
word mark Trademark on the blockchain through Cognate, Inc. CM
Certification-Registration Number: 10468217708
About Investorideas.com - News that
Inspires Big Investing Ideas
Investorideas.com
is a recognized news source publishing third party news, research and original
financial content. Learn about investing in stocks and sector trends with our
news alerts, articles, podcasts and
videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water,
renewable energy and more. Investor Idea’s original branded content includes
the following podcasts and columns : Crypto Corner , Play
by Play sports and stock news column, Investor Ideas
Potcasts Cannabis News and Stocks on the Move podcast and
column, Cleantech
and Climate Change , Exploring
Mining the AI
Eye .
Disclaimer/Disclosure: Investorideas.com is a
digital publisher of third party sourced news, articles and equity research as
well as creates original content, including video, interviews and articles.
Original content created by investorideas is protected by copyright laws other
than syndication rights. Our site does not make recommendations for purchases
or sale of stocks, services or products. Nothing on our sites should be
construed as an offer or solicitation to buy or sell products or securities.
All investing involves risk and possible losses. This site is currently
compensated for news publication and distribution, social media and marketing,
content creation and more. Disclosure is posted for each compensated news
release, content published /created if required but otherwise the news was not
compensated for and was published for the sole interest of our readers and
followers. Contact management and IR of each company directly regarding
specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other
news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations
of each country. Please read Investorideas.com privacy policy:
Investor Ideas does not condone the use of
cannabis except where permissible by law. Our site does not possess,
distribute, or sell cannabis products.
Contact Investorideas.com
800
665 0411
